{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:21:36Z","timestamp":1790112096637,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T00:00:00Z","timestamp":1562630400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T00:00:00Z","timestamp":1562630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40266-019-00693-6","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T12:53:31Z","timestamp":1562676811000},"page":"781-788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prasterone: A Review in Vulvovaginal Atrophy"],"prefix":"10.1007","volume":"36","author":[{"given":"Young-A","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,9]]},"reference":[{"issue":"4","key":"693_CR1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/GME.0000000000000768","volume":"24","author":"F Labrie","year":"2017","unstructured":"Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause. 2017;24(4):452\u201361.","journal-title":"Menopause."},{"key":"693_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2147\/IJWH.S158913","volume":"10","author":"I Naumova","year":"2018","unstructured":"Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health. 2018;10:387\u201395.","journal-title":"Int J Womens Health."},{"key":"693_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/978-3-319-63540-8_24","volume-title":"Pre-menopause, menopause and beyond: volume 5: frontiers in gynecological endocrinology","author":"F Labrie","year":"2018","unstructured":"Labrie F. Intravaginal DHEA for the treatment of vulvovaginal atrophy, intracrinology at work. In: Birkhaeuser M, Genazzani A, editors. Pre-menopause, menopause and beyond: volume 5: frontiers in gynecological endocrinology. Cham: Springer International Publishing; 2018. p. 269\u201384."},{"key":"693_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jsbmb.2014.09.003","volume":"145","author":"DF Archer","year":"2015","unstructured":"Archer DF. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy. J Steroid Biochem Mol Biol. 2015;145:139\u201343.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"693_CR5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/GME.0000000000000808","volume":"24","author":"F Labrie","year":"2017","unstructured":"Labrie F, Belanger A, Pelletier G, et al. Science of intracrinology in postmenopausal women. Menopause. 2017;24(6):702\u201312.","journal-title":"Menopause."},{"issue":"2","key":"693_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/GME.0000000000001177","volume":"26","author":"F Labrie","year":"2019","unstructured":"Labrie F. Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues. Menopause. 2019;26(2):220\u20134.","journal-title":"Menopause."},{"key":"693_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsbmb.2017.03.014","volume":"174","author":"DF Archer","year":"2017","unstructured":"Archer DF, Labrie F, Montesino M, et al. Comparison of intravaginal 6.5\u00a0mg (0.50%) prasterone, 0.3\u00a0mg conjugated estrogens and 10\u00a0\u03bcg estradiol on symptoms of vulvovaginal atrophy. J Steroid Biochem Mol Biol. 2017;174:1\u20138.","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"1","key":"693_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/2053369115626029","volume":"22","author":"CA Stuenkel","year":"2016","unstructured":"Stuenkel CA, Santen RJ. An introduction to the endocrine society clinical practice guideline on treatment of symptoms of the menopause. Post Reprod Health. 2016;22(1):6\u20138.","journal-title":"Post Reprod Health."},{"issue":"7","key":"693_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/GME.0000000000000921","volume":"24","author":"The North American Menopause Society","year":"2017","unstructured":"The North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728\u201353.","journal-title":"Menopause."},{"issue":"1","key":"693_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.maturitas.2015.02.003","volume":"81","author":"ECM Neves","year":"2015","unstructured":"Neves ECM, Birkhauser M, Samsioe G, et al. EMAS position statement: the ten point guide to the integral management of menopausal health. Maturitas. 2015;81(1):88\u201392.","journal-title":"Maturitas."},{"issue":"2","key":"693_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/13697137.2014.947254","volume":"18","author":"RJ Santen","year":"2015","unstructured":"Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18(2):121\u201334.","journal-title":"Climacteric."},{"key":"693_CR12","unstructured":"European Medicines Agency. Intrarosa: summary of product characteristics. 2019. http:\/\/www.ema.europa.eu\/ . Accessed 20 June 2019."},{"key":"693_CR13","unstructured":"AMAG Pharmaceuticals. Intrarosa (prasterone insert): US prescribing information. 2018. http:\/\/www.fda.gov . Accessed 31 May 2019."},{"key":"693_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jsbmb.2014.06.001","volume":"145","author":"F Labrie","year":"2015","unstructured":"Labrie F. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. J Steroid Biochem Mol Biol. 2015;145:133\u20138.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1\u20132","key":"693_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jsbmb.2007.09.023","volume":"109","author":"L Berger","year":"2008","unstructured":"Berger L, El-Alfy M, Labrie F. Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat. J Steroid Biochem Mol Biol. 2008;109(1\u20132):67\u201380.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"10","key":"693_CR16","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1111\/j.1743-6109.2012.02895.x","volume":"9","author":"G Pelletier","year":"2012","unstructured":"Pelletier G, Ouellet J, Martel C, et al. Effects of ovariectomy and dehydroepiandrosterone (DHEA) on vaginal wall thickness and innervation. J Sex Med. 2012;9(10):2525\u201333.","journal-title":"J Sex Med."},{"issue":"2","key":"693_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jsbmb.2005.02.018","volume":"96","author":"L Berger","year":"2005","unstructured":"Berger L, El-Alfy M, Martel C, et al. Effects of dehydroepiandrosterone, premarin and acolbifene on histomorphology and sex steroid receptors in the rat vagina. J Steroid Biochem Mol Biol. 2005;96(2):201\u201315.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"693_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3109\/13697137.2010.535226","volume":"14","author":"F Labrie","year":"2011","unstructured":"Labrie F, Archer DF, Bouchard C, et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric. 2011;14(2):282\u20138.","journal-title":"Climacteric."},{"issue":"9","key":"693_CR19","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1097\/GME.0000000000000428","volume":"22","author":"DF Archer","year":"2015","unstructured":"Archer DF, Labrie F, Bouchard C, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause. 2015;22(9):950\u201363.","journal-title":"Menopause."},{"issue":"3","key":"693_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/GME.0000000000000571","volume":"23","author":"F Labrie","year":"2016","unstructured":"Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243\u201356.","journal-title":"Menopause."},{"issue":"1","key":"693_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.maturitas.2015.02.005","volume":"81","author":"F Labrie","year":"2015","unstructured":"Labrie F, Archer DF, Bouchard C, et al. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas. 2015;81(1):46\u201356.","journal-title":"Maturitas."},{"key":"693_CR22","unstructured":"European Medicines Agency. Intrarosa: European public assessment report. 2017. http:\/\/www.ema.europa.eu . Accessed 20 June 2019."},{"key":"693_CR23","unstructured":"Archer D, Labrie F, Martel C, et al. Effect of age, time since menopause and previous hormone therapy on the response to intravaginal 6.5\u00a0mg prasterone [abstract no. S-4]. Menopause. 2018;25(12):1485."},{"issue":"11","key":"693_CR24","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1097\/GME.0000000000000910","volume":"24","author":"F Labrie","year":"2017","unstructured":"Labrie F, Archer DF, Martel C, et al. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause. 2017;24(11):1246\u201356.","journal-title":"Menopause."},{"issue":"12","key":"693_CR25","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1111\/jsm.13045","volume":"12","author":"F Labrie","year":"2015","unstructured":"Labrie F, Derogatis L, Archer DF, et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med. 2015;12(12):2401\u201312.","journal-title":"J Sex Med."},{"issue":"3","key":"693_CR26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1515\/hmbci-2015-0044","volume":"25","author":"C Bouchard","year":"2016","unstructured":"Bouchard C, Labrie F, Derogatis L, et al. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Horm Mol Biol Clin Investig. 2016;25(3):181\u201390.","journal-title":"Horm Mol Biol Clin Investig."},{"issue":"6","key":"693_CR27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3109\/13697137.2015.1077508","volume":"18","author":"F Labrie","year":"2015","unstructured":"Labrie F, Montesino M, Archer DF, et al. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. Climacteric. 2015;18(6):817\u201325.","journal-title":"Climacteric."},{"issue":"3","key":"693_CR28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3109\/09513590.2015.1110140","volume":"32","author":"M Montesino","year":"2016","unstructured":"Montesino M, Labrie F, Archer DF, et al. Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecol Endocrinol. 2016;32(3):240\u20135.","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"693_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/cncr.9014","volume":"93","author":"JT Keating","year":"2001","unstructured":"Keating JT, Wang HH. Significance of a diagnosis of atypical squamous cells of undetermined significance for Papanicolaou smears in perimenopausal and postmenopausal women. Cancer. 2001;93(2):100\u20135.","journal-title":"Cancer"},{"key":"693_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jsbmb.2016.03.016","volume":"159","author":"C Martel","year":"2016","unstructured":"Martel C, Labrie F, Archer DF, et al. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5\u00a0mg intravaginal prasterone for 12\u00a0weeks. J Steroid Biochem Mol Biol. 2016;159:142\u201353.","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"3","key":"693_CR31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1515\/hmbci-2015-0035","volume":"24","author":"Y Ke","year":"2015","unstructured":"Ke Y, Gonthier R, Simard JN, et al. Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA. Horm Mol Biol Clin Investig. 2015;24(3):117\u201329.","journal-title":"Horm Mol Biol Clin Investig."},{"issue":"12","key":"693_CR32","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/GME.0000000000000470","volume":"22","author":"DJ Portman","year":"2015","unstructured":"Portman DJ, Labrie F, Archer DF, et al. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause. 2015;22(12):1289\u201395.","journal-title":"Menopause."},{"issue":"3","key":"693_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.maturitas.2010.08.001","volume":"67","author":"RE Nappi","year":"2010","unstructured":"Nappi RE, Kokot-Kierepa M. Women\u2019s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67(3):233\u20138.","journal-title":"Maturitas."},{"issue":"1","key":"693_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3109\/13697137.2011.647840","volume":"15","author":"RE Nappi","year":"2012","unstructured":"Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA)\u2014results from an international survey. Climacteric. 2012;15(1):36\u201344.","journal-title":"Climacteric."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00693-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-019-00693-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00693-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T19:40:13Z","timestamp":1721504413000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-019-00693-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,9]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["693"],"URL":"https:\/\/doi.org\/10.1007\/s40266-019-00693-6","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,9]]},"assertion":[{"value":"9 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Young-A Heo is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}